HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kidney Inflammation Warning For PPI Omeprazole In Europe

Executive Summary

Cases of acute tubulointerstitial nephritis linked to omeprazole use flagged to the EMA leads to new product information warnings related to a possible risk of kidney inflammation for drugs containing the PPI sold in the EU.

You may also be interested in...



Swedish Drug And Device To Go Head-To-Head In The GERD Space

Two Swedish companies are working on tackling GERD – one with a drug, one with a device.

SCARs Label Warning For OTC PPIs In US Starts With Perrigo’s 131 Omeprazole Product Options

FDA approves warning for severe cutaneous adverse reactions on labeling for Perrigo's 131 20-mg omeprazole delayed-release tablet products across unflavored and cool mint or wild berry-mint options and 14-, 28- and 42-count packages. 

Rare Skin Allergy Warning Spreads To Nexium 24HR

FDA approves request after Nexium 24HR marketer Haleon responded March to changes-being-effected letter asking for label change to the delayed-release PPI.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel